Patient responses to genetic information: Studies of patients with hereditary cancer syndromes identify issues for use of genetic testing in nephrology practice

Seminars in Nephrology

Volumn 30, Issue 2, 2010, Pages 203-214

  Kaphingst, Kimberly A ^a   McBride, Colleen M ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Genetic counseling; Health literacy; Hereditary cancer syndromes; Risk perception; Screening behaviors

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ARTICLE; BREAST CANCER; CLINICAL TRIAL; COLORECTAL CANCER; EMOTION; FAMILIAL CANCER; FAMILY HISTORY; GENETIC COUNSELING; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SCREENING; HEALTH BEHAVIOR; HETEROZYGOTE; HIGH RISK POPULATION; HUMAN; KIDNEY DISEASE; MEDICAL DECISION MAKING; MUTATIONAL ANALYSIS; OVARY CANCER; PATIENT ATTITUDE; PATIENT EDUCATION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RISK ASSESSMENT; RISK REDUCTION; TREATMENT PLANNING;

EMOTIONS; GENETIC TESTING; HUMANS; NEOPLASMS; PATIENT EDUCATION AS TOPIC; PATIENTS; TRUTH DISCLOSURE;

EID: 77950482559     PISSN: 02709295     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2010.01.011     Document Type: Article

References (70)

1. Heshka J.T., Palleschi C., Howley H., Wilson B., Wells P.S. A systematic review of perceived risks, psychological and behavioral impacts of genetic testing. Genet Med 2008, 10:19-32.
2. Gene tests National Center for Biotechnology Information, [cited 2009 September 26]. http://www.genetests.org.
3. Guay-Woodford L.M., Knoers N.V.A.M. Genetic testing: considerations for pediatric nephrologists. Semin Nephrol 2009, 29:338-348.
4. Reed B., McFann K., Kimberling W.J., et al. Presence of de novo mutations in autosomal dominant polycystic kidney disease patients without family history. Am J Kidney Dis 2008, 52:1042-1050.
5. Sandford R.N. The diversity of PKD1 alleles: implications for disease pathogenesis and genetic counseling. Kidney Int 2009, 75:765-767.
6. Coleman J.A. Familial and hereditary renal cancer syndromes. Urol Clin North Am 2008, 35:563-572.
7. Linehan W.M., Pinto P.A., Srinivasan R., et al. Identification of the genes for kidney cancer: opportunity for disease-specific targeted therapeutics. Clin Cancer Res 2007, 13:671s-679s.
8. Hansel D.E., Rini B.I. Molecular genetics of hereditary renal cancer: new genes and diagnostic and therapeutic opportunities. Expert Rev Anticancer Ther 2008, 8:895-905.
9. Pfaffenroth E.C., Linehan W.M. Genetic basis for kidney cancer: opportunity for disease-specific approaches to therapy. Expert Opin Biol Ther 2008, 8:779-790.
10. Choyke P.L., Glenn G.M., Walther M.M., Zbar B., Linehan W.M. Hereditary renal cancers. RSNA 2002, 226:33-46.
11. Hwang J.J., Uchio E.M., Linehan W.M., Walther M.M. Hereditary kidney cancer. Urol Clin N Am 2003, 30:831-842.
12. Leach F.S. Linking human genetics with molecular medicine: will hereditary renal cancer play a major role?. Cancer Biol Ther 2004, 3:441-446.
13. Beery T.A., Williams J.K. Risk reduction and health promotion behaviors following genetic testing for adult-onset disorders. Genet Test 2007, 11:111-123.
14. Nielsen-Bohlman L., Panzer A.M., Kindig D.A. Health literacy: a prescription to end confusion 2004, National Academies Press, Washington, DC.
15. Guillem J.G., Wood W.C., Moley J.F., et al. ASCO/SSO review of current role of risk-reducing surgery in common hereditary cancer syndromes. J Clin Oncol 2006, 24:4642-4660.
16. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: recommendation statement. Ann Intern Med 2005, 143:355-361. US Preventive Services Task Force.
17. Rebbeck T.R., Kauff N.D., Domchek S.M. Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. J Natl Cancer Inst 2009, 101:80-87.
18. Grover S., Stoffel E.M., Mercado R.C., et al. Colorectal cancer risk perception on the basis of genetic test results in individuals at risk for Lynch syndrome. J Clin Oncol 2009, 27:3981-3986.
19. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol 2003, 21:2397-2406. American Society of Clinical Oncology.
20. Trepanier A., Ahrens M., McKinnon W., et al. Genetic cancer risk assessment and counseling: recommendations of the National Society of Genetic Counselors. J Genet Couns 2004, 13:83-114.
21. Biesecker B.B. Goals of genetic counseling. Clin Genet 2001, 60:323-330.
22. Wang C., Gonzalez R., Merajver S.D. Assessment of genetic testing and related counseling services: current research and future directions. Soc Sci Med 2004, 58:1427-1442.
23. Braithwaite D., Emery J., Walter F., Prevost T., Sutton S. Psychological impact of genetic counseling for familial cancer: a systematic review and meta-analysis. J Natl Cancer Inst 2004, 96:122-133.
24. Smerecnik C.M.R., Mester I., Verweij E., de Vries N.K., de Vries H. A systematic review of the impact of genetic counseling on risk perception accuracy. J Genet Couns 2009, 18:217-228.
25. Meiser B., Halliday J.L. What is the impact of genetic counselling in women at increased risk of developing hereditary breast cancer?. A meta-analytic review. Soc Sci Med 2002, 54:1463-1470.
26. Butow P.N., Lobb E.A., Meiser B., Barratt A., Tucker K.M. Psychological outcomes and risk perception after genetic testing and counselling in breast cancer: a systematic review. Med J Aust 2003, 178:77-81.
27. Cull A., Anderson E., Campbell S., et al. The impact of genetic counselling about breast cancer risk on women's risk perceptions and levels of distress. Br J Cancer 1999, 79:501-508.
28. Senay I., Kaphingst K.A. Anchoring-and-adjustment bias in communication of disease risk. Med Decis Making 2009, 29:193-201.
29. Hadley D.W., Jenkins J.F., Steinberg S.M., et al. Perceptions of cancer risks and predictors of colon and endometrial cancer screening in women undergoing genetic testing for Lynch syndrome. J Clin Oncol 2008, 26:948-954.
30. Aktan-Collan K., Haukkala A., Mecklin J.-P., Uutela A., Kaariainen H. Comprehension of cancer risk one and 12 months after predictive genetic testing for hereditary non-polyposis colorectal cancer. J Med Genet 2001, 38:787-792.
31. Hopwood P. Psychosocial aspects of risk communication and mutation testing in familial breast-ovarian cancer. Curr Opin Oncol 2005, 17:340-344.
32. Meiser B. Psychological impact of genetic testing for cancer susceptibility: an update of the literature. Psychooncology 2005, 14:1060-1074.
33. Vadaparampil S.T., Miree C.A., Wilson C., Jacobsen P.B. Psychosocial and behavioral impact of genetic counseling and testing. Breast Dis 2006, 27:97-108.
34. Nelson H.D., Huffman L.H., Fu R., Harris E.L. Genetic risk assessment and BRCA mutation testing for breast and ovarian cancer susceptibility: systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2005, 143:362-379.
35. Smith A.W., Dougall A.L., Posluszny D.M., et al. Psychological distress and quality of life associated with genetic testing for breast cancer risk. Psychooncology 2008, 17:767-773.
36. Lynch H.T., Snyder C., Lynch J.F., et al. Patient responses to the disclosure of BRCA mutation tests in hereditary breast-ovarian cancer families. Cancer Genet Cytogenet 2006, 165:91-97.
37. Low C.A., Bower J.E., Kwan L., Seldon J. Benefit finding in response to BRCA1/2 testing. Ann Behav Med 2008, 35:61-69.
38. Aktan-Collan K., Haukkala A., Mecklin J.-P., Uutela A., Kaariainen H. Psychological consequences of predictive genetic testing for hereditary non-polyposis colorectal cancer (HNPCC): a prospective follow-up study. Int J Cancer 2001, 93:608-611.
39. Hallowell N., Statham H., Murton F., Green J., Richards M. "Talking about chance": the presentation of risk information during genetic counseling for breast and ovarian cancer. J Genet Couns 1997, 6:269-286.
40. Edwards A., Gray J., Clarke A., et al. Interventions to improve risk communication in clinical genetics: systematic review. Patient Educ Couns 2008, 71:4-25.
41. Audrain J., Rimer B., Cella D., et al. Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want?. J Clin Oncol 1998, 16:133-138.
42. Lobb E., Butow P., Barratt A., et al. Communication and information-giving in high-risk breast cancer consultations: Influence on patient outcomes. Br J Cancer 2004, 90:321-327.
43. Meilleur K.G., Littleton-Kearney M.T. Interventions to improve patient education regarding multifactorial genetic conditions: a systematic review. Am J Med Genet 2009, 149A:819-830.
44. Chen W.Y., Garber J.E., Higham S., et al. BRCA1/2 genetic testing in the community setting. J Clin Oncol 2002, 20:4485-4492.
45. Graves K.D., Peshkin B.N., Halbert C.H., et al. Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors. Breast Cancer Res Treat 2007, 104:321-329.
46. Kinney A.Y., Simonsen S.E., Baty B.J., et al. Risk reduction behaviors and provider communication following genetic counseling and BRCA1 mutation testing in an African American kindred. J Genet Couns 2006, 15:293-305.
47. Lerman C., Hughes C., Croyle R.T., et al. Prophylactic surgery decisions and surveillance practices one year following BRCA1/2 testing. Prev Med 2000, 31:75-80.
48. Metcalfe K.A., Snyder C., Seidel J., et al. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer 2005, 4:97-103.
49. Peshkin B.N., Schwartz M.D., Isaacs C., et al. Utilization of breast cancer screening in a clinically based sample of women after BRCA1/2 testing. Cancer Epidemiol Biomarkers Prev 2002, 11:1115-1118.
50. Phillips K.-A., Jenkins M.A., Lindeman G.J., et al. Risk-reducing surgery, screening, and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clin Genet 2006, 70:198-206.
51. Scheuer L., Kauff N., Robson M., et al. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers. J Clin Oncol 2002, 20:1260-1268.
52. Schwartz M.D., Kaufman E., Peshkin B.N., et al. Bilateral prophylactic oophorectomy and ovarian cancer screening following BRCA1/BRCA2 mutation testing. J Clin Oncol 2003, 21:4034-4041.
53. Schwartz M.D., Lerman C., Brogan B., et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol 2004, 22:1823-1829.
54. Weitzel J.N., McCaffery S.M., Nedelcu R., et al. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg 2003, 138:1323-1328.
55. Collins V., Meiser B., Gaff C.St.John D.J.B., Halliday J. Screening and preventive behaviors one year after predictive genetic testing for hereditary nonpolyposis colorectal carcinoma. Cancer 2005, 104:273-278.
56. Hadley D.W., Jenkins J.F., Dimond E., et al. Colon cancer screening practices after genetic counseling and testing for hereditary nonpolyposis colorectal cancer. J Clin Oncol 2004, 22:39-44.
57. Halbert C.H., Lynch H., Lynch J., et al. Colon cancer screening practices following genetic testing for hereditary nonpolyposis colon cancer (HNPCC) mutations. Arch Intern Med 2004, 164:1881-1887.
58. Wagner A., van Kessel I., Kriege M.G., et al. Long term follow-up of HNPCC gene mutation carriers: compliance with screening and satisfaction with counseling and screening procedures. Fam Cancer 2005, 4:295-300.
59. Bowen D.J., Burke W., McTiernan A., Yasui Y., Andersen M.R. Breast cancer risk counseling improves women's functioning. Patient Educ Couns 2004, 53:79-86.
60. Calzone K.A., Prindiville S.A., Jourkiv O., et al. Randomized comparison of group versus individual genetic education and counseling for familial breast and/or ovarian cancer. J Clin Oncol 2005, 23:3455-3464.
61. Green M.J., Peterson S.K., Baker M.W., et al. Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial. JAMA 2004, 292:442-452.
62. Lerman C., Biesecker B., Berkendorf J.L., et al. Controlled trial of pretest education approaches to enhance informed decision-making for BRCA1 gene testing. J Natl Cancer Inst 1997, 89:148-157.
63. Lobb E., Butow P., Meiser B., et al. The use of audiotapes in consultations with women from high risk breast cancer families: a randomised trial. J Med Genet 2002, 39:697-703.
64. Mancini J., Nogues C., Adenis C., et al. Impact of an information booklet on satisfaction and decision-making about BRCA genetic testing. Eur J Cancer 2006, 42:871-881.
65. Miller S.M., Roussi P., Daly M.B., et al. Enhanced counseling for women undergoing BRCA1/2 testing: impact on subsequent decision making about risk reduction behaviors. Health Educ Behav 2005, 32:654-667.
66. Skinner C.S., Schildkraut J.M., Berry D., et al. Pre-counseling education materials for BRCA testing: does tailoring make a difference?. Genet Test 2002, 6:93-105.
67. van Roosmalen M., Stalmeier P., Verhoef L., et al. Randomised trial of a decision aid and its timing for women being tested for a BRCA1/2 mutation. Br J Cancer 2004, 90:333-342.
68. Wakefield C.E., Meiser B., Homewood J., et al. A randomized trial of a breast/ovarian cancer genetic testing decision aid used as a communication aid during genetic counseling. Psychooncology 2008, 17:844-854.
69. Wang C., Gonzalez R., Milliron K.J., Strecher V.J., Merajver S.D. Genetic counseling for BRCA1/2: a randomized controlled trial of two strategies to facilitate the education and counseling process. Am J Med Genet 2005, 134A:66-73.
70. Watson M., Duvivier V., Walsh M.W., et al. Family history of breast cancer: what do women understand and recall about their genetic risk?. J Med Genet 1998, 35:731-738.